Celgene Corporation (CELG)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
106.74-0.28 (-0.26%)
At close: 4:00 PM EDT

106.74 0.00 (0.00%)
After hours: 5:22 PM EDT

People also watch:
GILDBIIBREGNAMGNALXN
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open107.17
Prev Close107.02
Bid106.60 x 100
Ask106.75 x 200
Day's Range106.30 - 107.79
52wk Range93.05 - 128.39
1y Target EstN/A
Market Cap82.74B
P/E Ratio (ttm)45.11
Beta1.46
Volume2,548,554
Avg Vol (3m)4,514,186
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Benzinga4 hours ago

    Celgene To Surge By Double-Digits After Big Tumble, Vetr Crowd Says

    Shares of Celgene Corporation (NASDAQ: CELG ) have had ups and downs this year, but have ultimately lost roughly 11 percent since January. It seems like the Vetr crowd believes this has created an attractive ...

  • TheStreet.com5 hours ago

    Celgene's Deep Pullback Reaches Key Support

    For patient Celgene investors, a very low-risk buying opportunity is developing.

  • Barrons.com5 hours ago

    Novartis Disbands Cell Therapy Unit; What's Ahead For Kite, Juno?

    Quoting a letter sent to 400 staffers at the drug maker, Endpoints reported today that Novartis (NVS) is disbanding its pioneering cell and gene therapy unit, and folding it into other parts of the company. As the letter penned by Usman “Oz” Aman,” the Novartis executive who over saw the high-profile unit, read, “the risk of embarking on a new adventure in uncharted territory is that things don’t always work out as envisioned.” The news is having little impact on Novartis shareholders. As Piper Jaffrey analyst Joshua Schimmer and his team wrote today: For the broader autologous CAR-T field, we struggle with the implications of Novartis' move.